Pfizer Seeks To Invest In More Early Stage Research Companies - (The Wall Street Journal via NewsPoints Desk)

  • Pfizer indicated that it plans to broaden its R&D investment strategy to include partnerships with "early-stage" companies, reported The Wall Street Journal.
  • "The key for Pfizer is to be flexible in how we partner with different companies…we use a range of investment vehicles and collaboration models in R&D," remarked Mikael Dolsten, president of Pfizer worldwide R&D.
  • The drugmaker said the first four companies to benefit from its eased restrictions would receive $46 million in financing, with the investment targets conducting research in promising areas aligned with Pfizer's core interests.

To read more NewsPoints articles, click here.

Reference Articles